Monalizumab
Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A) . Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC) .
Product Specifications
CAS Number
1228763-95-8
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Chk | IFNAR
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
NBP2-82094G 0.1 mL
Rabbit Polyclonal ICBP90 Binding Protein 1 Antibody [DyLight 488]
Sign In for Pricing
View Details